purevax rcp
boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
respiporc flu3
ceva santé animale - inaktivirani virus influence / svinje - immunologicals - svinje - aktivna imunizacija svinja u dobi između 56 i dalje dana, uključujući i gestating krmača, protiv svinjske gripe uzrokovane podvrsta Н1n1, h3n2 i h1n2 za smanjenje kliničkih znakova i opterećenost pluća nakon infekcije. napad imuniteta: 7 dana nakon primarnog vaccinationduration imuniteta: 4 mjeseci svinja, cijepljene u dobi između 56 i 96 dana i 6 mjeseci u svinja, cijepljena prvi put u 96 dana i više. aktivna imunizacija gestating krmača nakon završetka primarnog cijepljenja, uvođenjem jedne doze 14 dana prije опороса da razviju visoki колостральных imunitet, koji pruža klinički zaštite prasadi, barem, nakon samo 33 dana nakon rođenja.
respiporc flupan h1n1
ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - imunološke, inaktivirane virusne vakcine za svinje, virus influence gripe - svinje - aktivna imunizacija svinja od dobi od 8 tjedana nadalje protiv pandemijskog virusa influence h1n1 svinjske gripe kako bi se smanjio virusni opterećenje pluća i virusni izlučivanje. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.
ig vena 50 g/l otopina za infuziju
kedrion s.p.a., ai conti, castelvecchio pascoli, barga (lucca), italija - imunoglobulin normalni, ljudski, intravenski - otopina za infuziju - 50 g/l - urbroj: 1 ml otopine sadrži: imunoglobulin normalni, ljudski, intravenski 50 mg (čistoće od najmanje 95% igg)
infanrix-ipv+hib prašak i suspenzija za suspenziju za injekciju cjepivo protiv difterije, tetanusa, pertusisa (nestanično, komponentno), poliomijelitisa (inaktivirano) i hemofilusa tipa b (konjugirano), adsorbirano
glaxosmithkline biologicals s.a., rue de l'institut 89, rixensart, belgija - toksoid difterije toksoid tetanusa toksoid hripavca filamentozni hemaglutinin hripavca pertaktin hripavca poliovirus tip 1, soj mahoney (inaktiviran) poliovirus tip 2, soj mef-1 (inaktiviran) poliovirus tip 3, soj saukett (inaktiviran) polisaharid hemofilusa influence tip b (poliribozilribitolfosfat) - prašak i suspenzija za suspenziju za injekciju - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži najmanje 30 iu toksoida difterije, najmanje 40 iu toksoida tetanusa, 25 µg toksoida hripavca, 25 µg filamentoznog hemaglutinina i 8 µg pertaktina adsorbirane na hidratizirani aluminijev hidroksid (0,5 mg al3+); inaktivirane polioviruse tip 1 (soj mahoney, 40 d-antigen jedinica), 2 (soj mef-1, 8 d-antigen jedinica) i 3 (soj saukett, 32 d-antigen jedinica); 10 µg polisaharida hemofilusa tip b (poliribozilribitolfosfat) konjugiranog na približno 30 µg toksoida tetanusa
flucelvax tetra
seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - gripa, ljudska - virus gripe, инактивированная, split ili površinski antigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra treba primjenjivati u skladu sa službenim preporukama.
pentaxim ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ ≥ 25 µg/0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml+ 10 µg/0.5 ml p
sanofi d.o.o. - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ ≥ 25 µg/0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml+ 10 µg/0.5 ml - 0,5 ml (1 doza ) pripremljene suspenzije sadrži: ≥ 30 i.j. prečišćeni toksoid difterije; ≥40 i.j prečišćeni toksoid tetanusa; 25 mcg antigen bordetella pertussis toksoid; 25 mcg antigen bordetella pertussis filamentozni hemaglutinin; 40 jedinica d antigena tip 1 poliomijelitis virus, inaktivisani; 8 jedinica d antig tip 2 poliomijelitis virus, inaktivisani; 32 jedinica d antigena tip 3 poliomijelitis virus, inaktivisani; 10 mcg polisaharid haemophilus influenzae tip b, konjugovani